Genticel Reports Final Results of GTL001 Phase 2 Trial in HPV16/18-Infected Women
13 déc. 2016 12h30 HE
|
Genticel S.A.
No statistical difference in viral clearance between treatment and placebo groups at any time point over 2 yearsNo difference in incidence of subjects progressing to high-grade cervical lesions...
GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
30 nov. 2016 08h00 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Appoints Eumedix as Strategic Advisor to Support Company’s Access to Innovative Drug Candidates
06 juil. 2016 12h35 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, July 06, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women
23 juin 2016 11h45 HE
|
Genticel S.A.
No statistical difference seen between treatment and placebo GTL001 development plan is under review Strategic pipeline development activities remain on trackAgreement with Serum Institute of India on...
Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria
15 juin 2016 16h01 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001
13 juin 2016 16h01 HE
|
Genticel S.A.
Ability to Use Clinically Validated hpv testsFive-Year Stability of GTL001 Drug Product PARIS and TOULOUSE, France, June 13, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels:...
Genticel Announces Publication in ‘Clinical Cancer Research’ of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001
01 juin 2016 13h10 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, June 01, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
20 avr. 2016 16h01 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, April 20, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces 2015 Annual Results and Strategic Update for 2016
14 mars 2016 09h21 HE
|
Genticel S.A.
Cash position of € 21.8 million as at December 31, 2015First income from partnership with Serum Institute of India Ltd recorded in 2015Operating expenses in line with 2015 clinical milestonesStrategic...
Genticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
27 janv. 2016 13h22 HE
|
Genticel S.A.
12- month primary endpoint not met in the overall populationStatistical difference in viral clearance rates in 2 predefined key subgroups DSMB recommends continuation of the study per protocol18-month...